期刊文献+

原发性肝癌患者的症状体验及症状群的研究进展 被引量:8

The Development of Symptom Interference and Symptom Clusters of HCC
原文传递
导出
摘要 原发性肝癌是最常见的恶性肿瘤之一,患者在患病期间会经历不同的症状,包括躯体症状(如疲乏、疼痛、消化道症状等)和心理症状.近十年来,对肝癌症状群的研究有了一定的进展,但是国内外护理专家对于肝癌症状群的结论并不尽相同,对于症状群的数目、构成、症状群出现的先后顺序,对于预后和治疗的影响以及群内各症状之间的关系等都存在争议.本文从肝癌患者的症状体验和症状群两方面进行综述,对国内外研究结果进一步探索和总结,以期为制订较为规范的症状管理措施提供参考和依据. The hepatocellular carcinoma (HCC) is one of the most common malignant tumors.Patients with hepatobiliary cancer suffer from multiple symptoms,such as physical symptoms and psychology symptoms.In recent years,along with the further research of symptoms,the concept of symptom clusters occurred.Those two issues have always been the hot topics in recent years.Through the efforts of experts at home and abroad,there has been a part of progress in this area.However,the results are not the same.There are lots of disputes in the numbers、sequence、incidences of the symptom clusters.The paper will discuss this issue from symptom experience and symptom clusters in order to provide the reference and basis for symptom management.
出处 《中国实用护理杂志》 2015年第14期1090-1092,共3页 Chinese Journal of Practical Nursing
关键词 肝肿瘤 症状 症状群 Liver neoplasms Symptom Symptom clusters
  • 相关文献

参考文献9

二级参考文献95

  • 1张思维,雷正龙,李光琳,邹小农,陈万青,赵平.中国肿瘤登记地区2005年发病死亡资料分析[J].中国肿瘤,2009,18(12):973-979. 被引量:33
  • 2Roberto Miraglia,Giada Pietrosi,Luigi Maruzzelli,Ioannis Petridis,Settimo Caruso,Gianluca Marrone,Giuseppe Mamone,Giovanni Vizzini,Angelo Luca,Bruno Gridelli.Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma[J].World Journal of Gastroenterology,2007,13(21):2952-2955. 被引量:40
  • 3陈竺.全国第三次死因回顾抽样调查报告[M].北京:中国协和医科大学出版社,2008:11-12.
  • 4Sebolt-Leopold JS, English JM. Mechanisms of drug inhibition of signalling molecules [ J ] . Nature, 2006, 441(7092): 457- 462.
  • 5Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase m randomised, double- blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34.
  • 6Lovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma [ J ] . N Engl J Med, 2008, 359(4): 378-390.
  • 7Ratain M J, Flaherty KT, Stadler WM, et al. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT) [ J ] . J Clin Oncol, 2004, 22(14S): 4501.
  • 8O'Dwyer PJ, Rosen M, Gallagher M, et al. Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma [ J ] . Proc Am Soc Clin Oncol, 2005, 23:193s.
  • 9Morin MJ. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumour and anti- angiogenic agents [ J ] . Oncogene, 2000, 19: 6574-6583.
  • 10Strumberg D, Awada A, Hirte H, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? [J]. Eur J Cancer, 2006, 42(4): 548-556.

共引文献735

同被引文献77

引证文献8

二级引证文献83

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部